BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.
Industry, Sector and Symbol:
- Sector: Basic Materials
- Industry: Specialty Chemicals - NEC
- Sub-Industry: N/A
- Symbol: NYSE:BIOA
- CUSIP: N/A
- Web: www.bio-amber.com
Capitalization:- Market Cap: $78.22 million
- Outstanding Shares: 37,073,000
Average Prices:- 50 Day Moving Avg: $2.48
- 200 Day Moving Avg: $2.90
- 52 Week Range: $1.88 - $6.50
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.17
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $8.94 million
- Price / Sales: 8.75
- Book Value: $1.87 per share
- Price / Book: 1.13
Profitability:- EBIDTA: ($24,410,000.00)
- Net Margins: -127.85%
- Return on Equity: -59.01%
- Return on Assets: -21.42%
Debt:- Debt-to-Equity Ratio: 0.46%
- Current Ratio: 1.19%
- Quick Ratio: 0.91%
Misc:- Average Volume: 78,035 shs.
- Beta: 2.61
- Short Ratio: 8.11
Frequently Asked Questions for BioAmber (NYSE:BIOA)
What is BioAmber's stock symbol?
BioAmber trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIOA."
How were BioAmber's earnings last quarter?
BioAmber Inc. (NYSE:BIOA) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.31) EPS for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.18. The company had revenue of $2.12 million for the quarter, compared to analyst estimates of $3.65 million. BioAmber had a negative return on equity of 59.01% and a negative net margin of 127.85%. View BioAmber's Earnings History.
When will BioAmber make its next earnings announcement?
Where is BioAmber's stock going? Where will BioAmber's stock price be in 2017?
2 analysts have issued 12-month price targets for BioAmber's shares. Their forecasts range from $3.00 to $5.50. On average, they anticipate BioAmber's share price to reach $4.25 in the next year. View Analyst Ratings for BioAmber.
Who are some of BioAmber's key competitors?
Some companies that are related to BioAmber include Atalaya Mining PLC (ATYM), Atalaya Mining PLC (EMED), Zotefoams plc (ZTF), Universal Stainless & Alloy Products (USAP), 22nd Century Group (XXII), DRDGOLD Limited (DRD), Griffin Mining Ltd (GFM), Goodrich Petroleum Corp (GDP), Firestone Diamonds PLC (FDI), Unique Fabricating (UFAB), Gem Diamonds Limited (GEMD), Platinum Group Metals Limited (PLG), Avino Silver and Gold Mines Ltd (ASM), Pershing Gold Corporation (PGLC), Unique Fabricating (UFAB), Hummingbird Resources Ltd (HUM), Northern Technologies International Corporation (NTIC) and Michelmersh Brick Holdings Plc (MBH).
Who are BioAmber's key executives?
BioAmber's management team includes the folowing people:
- Raymond J. Land, Chairman of the Board
- Fabrice Orecchioni, President, Chief Operating Officer
- Mario Settino, Chief Financial Officer
- Michael A. Hartmann, Executive Vice President
- James Millis, Chief Technology Officer
- Robert Frost, Director
- Kurt W. Briner, Independent Director
- Heinz Haller, Independent Director
- Ellen B. Richstone, Independent Director
- Kenneth W Wall, Independent Director
Who owns BioAmber stock?
BioAmber's stock is owned by many different of institutional and retail investors. Top institutional investors include NN Investment Partners Holdings N.V. (7.73%). Company insiders that own BioAmber stock include George Frederick John Gosbee, Jean-Francois Huc, Kenneth W Wall, Kurt W Briner, Michael A Hartmann and Raymond J Land. View Institutional Ownership Trends for BioAmber.
Who bought BioAmber stock? Who is buying BioAmber stock?
BioAmber's stock was acquired by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V.. Company insiders that have bought BioAmber stock in the last two years include George Frederick John Gosbee, Jean-Francois Huc, Kenneth W Wall, Kurt W Briner, Michael A Hartmann and Raymond J Land. View Insider Buying and Selling for BioAmber.
How do I buy BioAmber stock?
Shares of BioAmber can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioAmber's stock price today?
One share of BioAmber stock can currently be purchased for approximately $2.11.
MarketBeat Community Rating for BioAmber (NYSE BIOA)MarketBeat's community ratings are surveys of what our community members think about BioAmber and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for BioAmber (NYSE:BIOA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $4.25 (101.42% upside) |
Analysts' Ratings History for BioAmber (NYSE:BIOA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/17/2017 | Cowen and Company | Set Price Target | Hold | $3.00 | High |  |
| 3/13/2017 | AltaCorp Capital | Downgrade | Outperform -> Speculative | | Medium | |
| 8/7/2016 | Canaccord Genuity | Reiterated Rating | Buy | $5.50 | N/A | |
| 3/28/2016 | Credit Suisse Group | Boost Price Target | Outperform | $15.00 -> $17.00 | N/A | |
| 1/5/2016 | HC Wainwright | Reiterated Rating | Buy | $18.00 | N/A | |
| 1/5/2016 | Rodman & Renshaw | Initiated Coverage | Buy | $18.00 | N/A | |
(Data available from 7/27/2015 forward)
Earnings History for BioAmber (NYSE:BIOA)Earnings History by Quarter for BioAmber (NYSE BIOA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/7/2017 | | ($0.13) | | | | | N/A | |
| 5/9/2017 | 3/31/2017 | ($0.13) | ($0.31) | $3.65 million | $2.12 million | View | Listen | |
| 3/16/2017 | 12/31/2016 | ($0.19) | ($0.31) | $3.77 million | $0.63 million | View | N/A | |
| 11/3/2016 | Q216 | ($0.22) | ($0.26) | $3.75 million | $3.66 million | View | N/A | |
| 8/9/2016 | Q116 | ($0.27) | ($0.25) | $2.37 million | $2.50 million | View | N/A | |
| 3/14/2016 | Q415 | ($0.35) | ($0.40) | $0.98 million | $1.11 million | View | N/A | |
| 11/4/2015 | Q315 | ($0.41) | ($0.27) | $2.30 million | $0.35 million | View | N/A | |
| 3/12/2015 | Q414 | ($0.39) | ($0.48) | | ($0.31) million | View | N/A | |
| 11/6/2014 | Q3 2014 | ($0.40) | ($0.41) | | $0.47 million | View | N/A | |
| 8/7/2014 | Q2 2014 | ($0.40) | $0.40 | $0.45 million | $0.42 million | View | N/A | |
| 3/13/2014 | | ($0.36) | ($0.45) | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for BioAmber (NYSE:BIOA)Current Year EPS Consensus Estimate: $-0.43 EPS
Next Year EPS Consensus Estimate: $-0.23 EPS
Dividend History for BioAmber (NYSE:BIOA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for BioAmber (NYSE:BIOA)Insider Ownership Percentage: 8.33%
Institutional Ownership Percentage: 45.93%
Insider Trades by Quarter for BioAmber (NYSE:BIOA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/9/2016 | George Frederick John Gosbee | Director | Buy | 25,000 | $3.87 | $96,750.00 | |
| 11/8/2016 | Kurt W Briner | Director | Buy | 10,000 | $3.84 | $38,400.00 | |
| 5/24/2016 | Kurt W Briner | Director | Buy | 1,000 | $3.69 | $3,690.00 | |
| 5/23/2016 | Kurt W Briner | Director | Buy | 21,015 | $3.61 | $75,864.15 | |
| 5/11/2016 | Jean-Francois Huc | CEO | Buy | 10,000 | $3.22 | $32,200.00 | |
| 5/9/2016 | Kenneth W Wall | Director | Buy | 13,227 | $3.11 | $41,135.97 | |
| 5/6/2016 | Michael A Hartmann | EVP | Buy | 3,000 | $3.44 | $10,320.00 | |
| 12/3/2015 | Jean-Francois Huc | CEO | Sell | 27,278 | $8.11 | $221,224.58 | |
| 12/3/2015 | Michael A. Hartmann | EVP | Sell | 21,477 | $8.11 | $174,178.47 | |
| 8/14/2015 | Michael A Hartmann | EVP | Buy | 1,500 | $6.75 | $10,125.00 | |
| 8/11/2015 | Jean-Francois Huc | CEO | Buy | 4,000 | $6.18 | $24,720.00 | |
| 8/10/2015 | Raymond J Land | Director | Buy | 1,500 | $6.71 | $10,065.00 | |
| 5/6/2015 | Jean-Francois Huc | CEO | Buy | 8,800 | $9.00 | $79,200.00 | |
| 5/6/2015 | Kurt W Briner | Director | Buy | 10,000 | $9.00 | $90,000.00 | |
| 5/6/2015 | Michael A Hartmann | EVP | Buy | 1,100 | $9.00 | $9,900.00 | |
| 12/11/2014 | Kenneth W Wall | Director | Buy | 3,000 | $9.20 | $27,600.00 | |
| 12/10/2014 | Kenneth W Wall | Director | Buy | 5,000 | $9.30 | $46,500.00 | |
| 11/10/2014 | Kurt W Briner | Director | Buy | 15,000 | $9.35 | $140,250.00 | |
| 9/9/2014 | Kurt W Briner | Director | Buy | 5,000 | $12.00 | $60,000.00 | |
| 8/25/2014 | Kurt W Briner | Director | Buy | 14,250 | $11.50 | $163,875.00 | |
| 8/11/2014 | Kurt W Briner | Director | Buy | 2,980 | $11.45 | $34,121.00 | |
| 7/16/2014 | Jean-Francois Huc | CEO | Buy | 4,000 | $12.00 | $48,000.00 | |
| 7/16/2014 | Michael A Hartmann | EVP | Buy | 3,000 | $12.00 | $36,000.00 | |
| 5/12/2014 | Andrew P Ashworth | CFO | Buy | 3,000 | $10.00 | $30,000.00 | |
| 5/12/2014 | Michael A Hartmann | EVP | Buy | 2,500 | $10.05 | $25,125.00 | |
| 11/14/2013 | Kurt W Briner | Director | Buy | 7,200 | $6.95 | $50,040.00 | |
| 9/3/2013 | Michael A Hartmann | EVP | Buy | 2,000 | $4.63 | $9,260.00 | |
| 8/29/2013 | Jean-Francois Huc | CEO | Buy | 5,000 | $4.25 | $21,250.00 | |
| 8/15/2013 | Kurt W Briner | Director | Buy | 13,000 | $5.49 | $71,370.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for BioAmber (NYSE:BIOA)
Latest Headlines for BioAmber (NYSE:BIOA)
| Source: |
|
| Date | Headline |
|---|
 | BioAmber Inc. (NYSE:BIOA) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - July 26 at 5:02 PM |
 | Global Bio-Based Chemicals Market Forecast 2017-2025 - PR Newswire (press release)
www.prnewswire.com - July 20 at 11:11 PM |
 | Succinic Acid - Global Strategic Business Report 2017 - Rising Demand for Bio-Plastics: Opportunity for Bio-Succinic Acid Market
www.finanznachrichten.de - July 16 at 9:11 PM |
| BioAmber Inc. (BIOA) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - July 11 at 7:14 PM |
| Comparing BioAmber (NYSE:BIOA) and Kraton Corporation (KRA)
www.americanbankingnews.com - July 9 at 8:22 AM |
| BioAmber (NYSE:BIOA) & Rayonier Advanced Materials (RYAM) Head-To-Head Comparison
www.americanbankingnews.com - July 7 at 8:06 AM |
| BioAmber Inc. (BIOA) Lifted to Sell at ValuEngine
www.americanbankingnews.com - June 24 at 12:38 AM |
 | BioAmber (BIOA) Announces Launch of BIO-SA Pharmaceutical Grade - StreetInsider.com
www.streetinsider.com - June 16 at 4:39 PM |
| BioAmber (BIOA) Announces Launch of BIO-SA Pharmaceutical Grade
www.streetinsider.com - June 15 at 5:43 PM |
 | BioAmber Launches a Pharmaceutical Grade for its Bio-succinic Acid
finance.yahoo.com - June 15 at 5:43 PM |
| BioAmber Inc. (BIOA) Lowered to "Strong Sell" at ValuEngine
www.americanbankingnews.com - June 12 at 12:40 AM |
 | TMX Group Equity Financing Statistics - May 2017
www.marketwatch.com - June 7 at 4:12 PM |
| Global Organic Acid Market, Competition Forecast and Opportunities, 2026 - Research and Markets
www.finanznachrichten.de - May 29 at 9:13 AM |
| BioAmber Announces Changes to its Board of Directors, the Appointment of a Chief Financial Officer and the Results ... - PR Newswire (press release)
www.prnewswire.com - May 17 at 8:59 PM |
 | Law Offices of Howard G. Smith Reminds BioAmber Inc. Investors of Pending Lawsuit and Upcoming Lead Plaintiff ... - Business Wire (press release)
www.businesswire.com - May 17 at 8:59 PM |
| Law Offices of Howard G. Smith Reminds BioAmber Inc. Investors of Pending Lawsuit and Upcoming Lead Plaintiff Deadline
finance.yahoo.com - May 16 at 4:00 PM |
| BIOA DEADLINE ALERT: The Law Offices of Vincent Wong Notifies Investors of BioAmber Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 17, 2017 - BIOA
finance.yahoo.com - May 16 at 4:00 PM |
| BIOA ALERT: Rosen Law Firm Reminds BioAmber Inc. Investors of Important May 17 Deadline in First Filed Class Action - BIOA
finance.yahoo.com - May 16 at 12:37 PM |
| DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against BioAmber Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 16 at 12:37 PM |
| Bioamber Inc (BIOA) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - May 15 at 4:28 PM |
| BioAmber (BIOA) Names New CFO and Announces Changes to Board of Directors
www.streetinsider.com - May 15 at 4:04 PM |
| DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against BioAmber Inc. (BIOA) & Lead Plaintiff Deadline: May 17, 2017
finance.yahoo.com - May 15 at 4:04 PM |
| 2-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against BioAmber Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 15 at 4:04 PM |
| UPCOMING DEADLINE ALERT: Levi & Korsinsky, LLP Reminds Shareholders of BioAmber Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 17, 2017 - BIOA
finance.yahoo.com - May 15 at 4:04 PM |
 | BRIEF-BioAmber says Mario Settino appointed CFO
www.reuters.com - May 15 at 9:31 AM |
| BioAmber Announces Changes to its Board of Directors, the Appointment of a Chief Financial Officer and the Results of its Annual Stockholders Meeting
finance.yahoo.com - May 15 at 9:31 AM |
 | BioAmber (BIOA) Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 14 at 4:03 PM |
| 5-DAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against BioAmber Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 13 at 2:32 AM |
| BIOA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of BioAmber Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 17, 2017 - BIOA
finance.yahoo.com - May 12 at 4:30 PM |
| BioAmber, Inc. :BIOA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 4:30 PM |
| 6-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against BioAmber Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 11 at 9:30 PM |
| ONE WEEK DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against BioAmber Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 11 at 2:11 AM |
| Edited Transcript of BIOA earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 9:10 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of BioAmber Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 17, 2017 - BIOA
finance.yahoo.com - May 10 at 4:09 PM |
| Bioamber Inc (BIOA) Posts Earnings Results, Misses Estimates By $0.18 EPS
www.americanbankingnews.com - May 10 at 1:30 PM |
| BioAmber Reports First Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - May 10 at 8:48 AM |
| BioAmber Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 8:58 PM |
| DEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Those with Losses in Excess of $100,000 from Investment in BioAmber Inc. to Contact the Firm
finance.yahoo.com - May 9 at 8:58 PM |
| APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against BioAmber Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 9 at 8:58 PM |
| BioAmber posts 1Q profit
finance.yahoo.com - May 9 at 8:58 PM |
| BIOA Investors: GPM Reminds Investors of the May 17 Deadline in the Class Action Lawsuit Against BioAmber Inc.
finance.yahoo.com - May 9 at 3:56 PM |
| The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of BioAmber Inc. Shareholders and a Lead Plaintiff Deadline of May 17, 2017 (BIOA)
finance.yahoo.com - May 9 at 3:56 PM |
| SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against BioAmber Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 8 at 8:49 PM |
| Bioamber Inc (BIOA) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:16 AM |
| SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against BioAmber Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 6 at 1:59 AM |
| DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against BioAmber Inc. (BIOA) and Lead Plaintiff Deadline: May 17, 2017
finance.yahoo.com - May 5 at 3:56 PM |
| Somewhat Positive Media Coverage Extremely Likely to Affect Bioamber (BIOA) Share Price
www.americanbankingnews.com - May 4 at 9:42 AM |
| BioAmber Announces Trading on Toronto Stock Exchange Market Commencing on May 3, 2017 - Special Warrant ... - MarketWatch
www.marketwatch.com - May 3 at 6:13 PM |
| INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against BioAmber Inc. and Reminds ... - Yahoo Finance
finance.yahoo.com - May 3 at 6:13 PM |
| INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against BioAmber Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - May 3 at 6:13 PM |
BioAmber (BIOA) Chart for Thursday, July, 27, 2017
